Form 8-K OSIRIS THERAPEUTICS, For: Aug 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/22/2026
- Wall Street indexes dip with technology earnings, rising oil in focus
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Oil settles up more than 3% to six-week high as Mideast conflict threatens oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
- Emirates refusing to take delivery of first 10 Boeing 777X jets
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- Crude Inventory Rose 2 Million Barrels Last Week - EIA
- Wall St ends higher on chip stocks recovery; earnings in focus
- Palo Alto Networks to acquire Embrace to expand observability tools
Osiris Therapeutics (OSIR) Misses Q2 EPS by 20c
August 7, 2014 8:12 AM EDTOsiris Therapeutics (NASDAQ: OSIR) reported Q2 EPS of ($0.04), $0.20 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $13.3 million versus the consensus estimate of $11 million.
For earnings history and earnings-related data on Osiris Therapeutics (OSIR) click here.
... More